{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T14:11:57Z","timestamp":1790863917911,"version":"4.1.0"},"reference-count":21,"publisher":"Public Library of Science (PLoS)","issue":"6","license":[{"start":{"date-parts":[[2011,6,14]],"date-time":"2011-06-14T00:00:00Z","timestamp":1308009600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0020899","type":"journal-article","created":{"date-parts":[[2011,6,17]],"date-time":"2011-06-17T16:39:51Z","timestamp":1308328791000},"page":"e20899","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":58,"title":["The Combination of RAD001 and NVP-BEZ235 Exerts Synergistic Anticancer Activity against Non-Small Cell Lung Cancer In Vitro and In Vivo"],"prefix":"10.1371","volume":"6","author":[{"given":"Cheng-Xiong","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yikun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Yue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taofeek K.","family":"Owonikoko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suresh S.","family":"Ramalingam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fadlo R.","family":"Khuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shi-Yong","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2011,6,14]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ccr.2004.06.007","article-title":"The LKB1 tumorsuppressor negatively regulates mTOR signaling.","volume":"6","author":"RJ Shaw","year":"2004","journal-title":"Cancer Cell"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1038\/sj.bjc.6604515","article-title":"Role of LKB1 in lung cancer development.","volume":"99","author":"L Makowski","year":"2008","journal-title":"Br J Cancer"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1038\/nature07423","article-title":"Somatic mutations affect key pathways in lung adenocarcinoma.","volume":"455","author":"L Ding","year":"2008","journal-title":"Nature"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/S0140-6736(08)61039-9","article-title":"Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial.","volume":"372","author":"RJ Motzer","year":"2008","journal-title":"Lancet"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1158\/1078-0432.CCR-06-2798","article-title":"The mammalian target of rapamycin signaling pathway: twists and turns in the road to cancer therapy.","volume":"13","author":"RT Abraham","year":"2007","journal-title":"Clin Cancer Res"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1158\/1535-7163.MCT-08-0017","article-title":"Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase\/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity.","volume":"7","author":"SM Maira","year":"2008","journal-title":"Mol Cancer Ther"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"7644","DOI":"10.1158\/0008-5472.CAN-09-0823","article-title":"Dual phosphoinositide 3-kinase\/mammalian target of rapamycin blockade is an effective radiosensitizing strategy for the treatment of non-small cell lung cancer harboring K-RAS mutations.","volume":"69","author":"G Konstantinidou","year":"2009","journal-title":"Cancer Res"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1038\/nm.1890","article-title":"Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers.","volume":"14","author":"JA Engelman","year":"2008","journal-title":"Nat Med"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"7409","DOI":"10.1158\/0008-5472.CAN-08-1522","article-title":"Enhancing mammalian target of rapamycin (mTOR)-targeted cancer therapy by preventing mTOR\/raptor inhibition-initiated, mTOR\/rictor-independent Akt activation.","volume":"68","author":"X Wang","year":"2008","journal-title":"Cancer Res"},{"key":"ref10","first-page":"4931","article-title":"Differential effects of synthetic nuclear retinoid receptor-selective retinoids on the growth of human non-small cell lung carcinoma cells.","volume":"57","author":"SY Sun","year":"1997","journal-title":"Cancer Res"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.4161\/cbt.7.12.6944","article-title":"Overcoming mTOR inhibition-induced paradoxical activation of survival signaling pathways enhances mTOR inhibitors' anticancer efficacy.","volume":"7","author":"X Wang","year":"2008","journal-title":"Cancer Biol Ther"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1093\/jnci\/djh322","article-title":"Death receptor regulation and celecoxib-induced apoptosis in human lung cancer cells.","volume":"96","author":"X Liu","year":"2004","journal-title":"J Natl Cancer Inst"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1038\/sj.onc.1202543","article-title":"Mechanisms of apoptosis induced by the synthetic retinoid CD437 in human non-small cell lung carcinoma cells.","volume":"18","author":"SY Sun","year":"1999","journal-title":"Oncogene"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1593\/neo.10704","article-title":"Protein phosphatase 2A negatively regulates eukaryotic initiation factor 4E phosphorylation and eIF4F assembly through direct dephosphorylation of Mnk and eIF4E.","volume":"12","author":"Y Li","year":"2010","journal-title":"Neoplasia"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"7052","DOI":"10.1158\/0008-5472.CAN-05-0917","article-title":"Activation of Akt and eIF4E Survival Pathways by Rapamycin-Mediated Mammalian Target of Rapamycin Inhibition.","volume":"65","author":"SY Sun","year":"2005","journal-title":"Cancer Res"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"pe24","DOI":"10.1126\/scisignal.267pe24","article-title":"The pharmacology of mTOR inhibition.","volume":"2","author":"DA Guertin","year":"2009","journal-title":"Sci Signal"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"222","DOI":"10.4161\/cbt.2.3.360","article-title":"Rapamycins: mechanism of action and cellular resistance.","volume":"2","author":"S Huang","year":"2003","journal-title":"Cancer Biol Ther"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ccr.2007.05.008","article-title":"Defining the role of mTOR in cancer.","volume":"12","author":"DA Guertin","year":"2007","journal-title":"Cancer Cell"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"8022","DOI":"10.1158\/0008-5472.CAN-08-1385","article-title":"NVP-BEZ235, a dual PI3K\/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations.","volume":"68","author":"V Serra","year":"2008","journal-title":"Cancer Res"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1517\/14728220903225008","article-title":"Enhancing mTOR-targeted cancer therapy.","volume":"13","author":"X Wang","year":"2009","journal-title":"Expert Opin Ther Targets"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.molcel.2006.03.029","article-title":"Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt\/PKB.","volume":"22","author":"D Sarbassov dos","year":"2006","journal-title":"Mol Cell"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0020899","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,10,23]],"date-time":"2018-10-23T18:56:18Z","timestamp":1540320978000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0020899"}},"subtitle":[],"editor":[{"given":"Gen Sheng","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2011,6,14]]},"references-count":21,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2011,6,14]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0020899","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,6,14]]}}}